Evista for Osteoporosis

Evista (chemical name: raloxifene) is a selective estrogen receptor modulator (SERM) approved by the FDA to treat and prevent osteoporosis in postmenopausal women.

Evista also is approved to reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women diagnosed with osteoporosis, as well as postmenopausal women who don’t have osteoporosis but who are at higher-than-average risk for breast cancer.

Evista is a pill taken by mouth once a day.

Learn more about Evista.